In the next issue of Pharma Technology Focus, we find out about a new class of cancer therapeutics developed by Cybrexa, which looks to identify combinations of chemotherapy and DNA inhibitors to increase efficacy and reduce toxicity in cancer treatment, and explore the environmental impact of clinical antidepressants entering waters around the UK. 

Also, we speak to LNC Therapeutics to find out if the company’s exclusive license agreement with Cornell University for its Christensenella patent family could form the foundation for the first drugs using microbiome bacteria, and take a look at a new app developed by Roche, which may help physicians to match patients to clinical trials.

Plus, we examine the results of Eli Lilly’s GIP and GLP-1 receptor agonist, which showed strong and clinically meaningful blood sugar reduction and weight loss in people with type 2 diabetes, and investigate how pharma companies and the supply chain tackle the challenges of controlling an epidemic in an uncontrollable environment.